In the quarter following its FDA approval on June 18 of last year, Gilead Sciences rolled out Yeztugo as the successor to its blockbuster HIV therapy Biktarvy. Company projections indicate that Yeztugo will generate approximately $100 million in sales in Q4, driven by early uptake in both U.S. and European treatment centers. Analysts note that this rapid ramp reflects strong positioning against competitive oral regimens and underscores Gilead’s ability to convert regulatory milestones into commercial momentum.

Even as certain oncology franchises delivered below-forecast revenues in Q3, Gilead’s disciplined cost management and improved manufacturing efficiency propelled its EBIT margin to 45.2%, the highest level in three years. The expansion was supported by a 7% reduction in operating expenses compared to the same period last year, driven primarily by lower milestone payments and streamlined R&D expenditures in non-core programs.

In the latest trading session, Gilead outpaced major indices with a 1.23% gain, extending its year-to-date outperformance to approximately 8%. This resilience has attracted renewed attention from institutional investors, with five large-cap mutual funds increasing their exposure to the stock over the past month. Market strategists attribute the move to confidence in the company’s expanding HIV portfolio and improving margin profile.